immunotherapy

pipeline pipes RD research

Biotech

PDS halts ph. 3 cancer therapy to focus on colorectal contender

PDS Biotechnology has called time on its phase 3 head and neck cancer therapy to channel resources to a metastatic colorectal cancer drug in phase 2.

James Waldron Aug 13, 2026 9:55am

Cancer mutation precision medicine oncology targeted

BIO 2026: How a gut feeling transformed cancer treatment forever

Jun 25, 2026 9:23am

Person throwing piece of paper into full waste bin

Fierce Pharma

Nature retracts provocative PD-1 time-of-day study

Jun 24, 2026 11:00am

Golfer devastated after just barely missing a putt

Immutep's ph. 3 failure surprises analysts, sinks stock

Mar 13, 2026 9:53am

Asia map globe

Dr. Reddy's pens $370M pact for rights to Immutep's LAG-3 agent

Dec 8, 2025 10:55am

spray painting

BMS-backed Dispatch unveils with $216M, Carl June as cofounder

Jul 23, 2025 6:30am